Hospitalized trauma patients frequently suffer from blood clots in the legs or lungs. To minimize the risk of these blood clots developing, patients may be given a blood-thinner drug such as enoxaparin. Until now, a set dose of enoxaparin has been given to a patient, regardless of his or her weight. However, a recent study suggests that for obese patients, the set dose may be inadequate. The purpose of this study is to evaluate whether or not a dose of enoxaparin that is based on the patient's weight will help to prevent the formation of blood clots. The information gathered through this study will help doctors to understand the best way to prevent blood clots in future trauma patients. The potential risks of participating in this study include the minor risks of blood draws and ultrasounds, as well as the more significant risks of bleeding as a side effect of the enoxaparin.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
1,200
Intermountain Medical Center
Murray, Utah, United States
Asymptomatic lower-extremity DVT identified during hospitalization
Time frame: Hospitalization
Symptomatic lower extremity DVT during hospitalization and at 90 days
Time frame: 90 Days
Asymptomatic proximal DVT during hospitalization
Time frame: Hospitalization
Symptomatic proximal DVT during hospitalization and at 90 days
Time frame: 90 Days
Symptomatic upper-extremity DVT during hospitalization and at 90 days
Time frame: 90 Days
Symptomatic PE during hospitalization and at 90 Days
Time frame: 90 Days
Major Bleeding
Major Bleeding as defined by the criteria of the International Society of Thrombosis.
Time frame: Hospitalization and at 90 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.